Healthcare Professional Portal

Return to portal
Register
Register

Click here for prescribing information and adverse event reporting information (hosted externally).

Our Services
PI & AE

QUVIVIQ™ is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.1

Gain access to resources on chronic insomnia

Subscribe for updates from us on the management of chronic insomnia, expert speaker videos from congresses and other events, as well as useful infographics, patient support items, and more!

Click here to go back
Click here to go back
Register and stay up to date with the latest news about QUVIVIQ™, chronic insomnia and sleep science. By registering and ticking this box you are confirming you have read and agreed to the Informed Consent and Privacy Policy and you herewith consent to the processing of your personal data in line therewith.

Insomnia Conversation Starter

Discuss key domains to uncover your patients’ insomnia

Click here to go back
Click here to go back

This medicine is subject to additional monitoring.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to Idorsia at ds.safety.uk@idorsia.com.

This information is intended for UK healthcare professionals.

References

  1. QUVIVIQ™ (daridorexant) Summary of Product Characteristics

UK-DA-00922 | Last updated: July 2025

Copyright © 2026 Idorsia Pharmaceuticals Ltd

Register here

QUV-Pro.idorsia QUVIVIQ Register_June 2025

Register and stay up to date with the latest news in insomnia management, safety trends and sleep science:

Click here to go back
Register and stay up to date with the latest news in QUVIVIQ™ management, safety trends and sleep science. By registering and ticking this box you are confirming you have read and agreed to the Informed Consent and Privacy Policy and you herewith consent to the processing of your personal data in line therewith.

Lead the Way in Insomnia Treatment

Register to Download Your Essential Guide for Unveiling Patient Insomnia Symptoms

Insomnia Conversation starter printable PDF

Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google play or Apple App store. Adverse events should also be reported to ds.safety.uk@idorsia.com.

This site is intended only for healthcare professionals resident in the United Kingdom.

UK-DA-00255 | Date of preparation: April 2024
Copyright © 2026 Idorsia Pharmaceuticals Ltd

Welcome to the Idorsia UK
Healthcare Professional portal

This information is intended for UK Healthcare Professionals only.

By entering this site you are confirming that you are a UK Healthcare Professional.

I am a UK healthcare professional
I am a member of the public

UK-DA-00217 | Date of preparation: October 2023

Copyright © 2023 Idorsia Pharmaceuticals Ltd

What your patients need to know

At Month 3, consistent nightly use of QUVIVIQ™ ▼ (daridorexant) 50 mg helped patients:2

QUVIVIQ™▼(daridorexant) should be taken in the evening, within 30 minutes before bed1

Time to sleep onset may be delayed if taken with, or soon after, a large meal1

The consumption of grapefruit or grapefruit juice in the evening should be avoided1

Patients should be cautioned about drinking alcohol during treatment with QUVIVIQ™. Individuals with a history of abuse of or addiction to alcohol or other substances may be at increased risk for abuse of QUVIVIQ™ and should be monitored carefully1

Continue to practise good sleep habits5

The maximum daily dose of QUVIVIQ™ is 50 mg.1 If a patient forgets to take QUVIVIQ™ at bedtime, that dose should not be taken during the night1

Night and day efficacy improves over time with consistent nightly use from baseline versus placebo2,4

Patients should be cautioned about engaging in potentially hazardous activities, driving, o operating heavy machinery unless they feel fully alert. A period of approximately 9 hours is recommended between taking QUVIVIQ™ and driving or using machines1

For more information, please refer to the QUVIVIQ™ Patient Information Leaflet.

Prescribing information and adverse event reporting (hosted externally) ›

References: 1. QUVIVIQ™ (daridorexant) SmPC; 2. Mignot E et al. Lancet Neurol 2022;21:125-139; 4. Kunz D et al. CNS Drugs 2023;37:93-106; 5. Sleep Foundation. Accessed July 2025

CLOSE
Welcome back!

Please complete the form below to sign in.

You don’t have an account? 

Sign up

You are now leaving pro.idorsia.uk

You will now be redirected to an independent third party site that is maintained outside of this website, where all Idorsia Pharmaceuticals Ltd UK’s medicines can be found: the electronic Medicines Compendium (eMC)

Continue to medicines.org.uk

UK-DA-00439 | Date of preparation: May 2024

Copyright ©2026 Idorsia Pharmaceuticals Ltd

Gain access to resources on chronic insomnia

Fill in the form below to get instant access to this resource and unlock our full library of downloadable materials.

You are now leaving pro.idorsia.uk

You are now leaving pro.idorsia.uk. You will now be redirected to an independent third-party site that is maintained outside of this website.
You are now leaving pro.idorsia.uk. The linked website provides helpful information if you are having trouble sleeping. It is neither owned or controlled by Idorsia Pharmaceuticals Ltd. Idorsia accepts no responsibility for the content or services of the linked site.
Cancel
Go to link

UK-DA-00445 | Date of preparation: May 2024

Copyright ©2026 Idorsia Pharmaceuticals Ltd

Confirming your contact information and preferences means that you agree that we, Idorsia, manage your personal data in our Client Relationship Management system to document, customise, plan, and conduct our interactions with you and, to analyse and segment your interactions, interests, preferences, and scientific activities in order to interact with you in a way we think is most relevant to you.

It also means that you agree that we will send you Idorsia standard or personalised medical, company or product related information and material via email based on your choices and on what we think is of interest to you. You further consent that we process your personal data for this.

For more information about us, our processing of your personal data and your rights, please see our Privacy Notice.

Create an account
Access our in-depth e-learning resources on chronic insomnia
Title *
First name *
Last name *
Professional email *
Password *
Specialty *
Professional registration number *

Select below to keep informed of further resources:

You already have an account? 

Sign in

Gain access to resources on chronic insomnia​

Register to get access to:

  • Insightful videos
  • Patient resources
  • E-Learning programme
  • And details about us and our offerings